
Get exclusive money-saving offers and guides
Straight to your inbox
Updated
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Kazia Therapeutics Limited is a biotechnology business based in Australia. Kazia Therapeutics shares (KZA) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Kazia Therapeutics has a trailing 12-month revenue of around $988,110..
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | $0.37 - $1.235 |
---|---|
50-day moving average | $0.9129 |
200-day moving average | $0.6308 |
Target price | $0.22 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.179 |
Standard brokerage - Australian shares
Competitive broker fees on Australian and international shares
Important: Share trading carries risk of capital loss.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of A$0.815 on 2020-10-22
1 week (2021-01-14) | -40.51% |
---|---|
1 month (2020-12-21) | -30.34% |
3 months (2020-10-21) | -2.98% |
6 months (2020-07-21) | 48.18% |
1 year (2020-01-21) | 30.40% |
---|---|
2 years (2019-01-21) | 94.05% |
3 years (2018-01-19) | 81.11% |
5 years (2016-01-21) | -29.13% |
Revenue TTM | $988,110 |
---|---|
Gross profit TTM | $988,110 |
Return on assets TTM | -34.45% |
Return on equity TTM | -88.05% |
Profit margin | 0% |
Book value | 0.149 |
Market capitalisation | $93.8 million |
TTM: trailing 12 months
We're not expecting Kazia Therapeutics to pay a dividend over the next 12 months.
Kazia Therapeutics 's shares were split on a 1:10 basis on 17 November 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kazia Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Kazia Therapeutics shares which in turn could have impacted Kazia Therapeutics 's share price.
Over the last 12 months, Kazia Therapeutics 's shares have ranged in value from as little as $0.37 up to $1.235. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Kazia Therapeutics 's is 2.133. This would suggest that Kazia Therapeutics 's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
Steps to owning and managing ETFS FANG+ ETF units.
Steps to owning and managing ETFS S&P Biotech ETF units.
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.
Steps to owning and managing BetaShares India Quality ETF units.